Intellia Therapeutics, Inc.
NTLA
Updated: 23/09/2026, 06:57:49
Intellia Therapeutics, Inc. is a biotechnology firm dedicated to advancing therapeutic treatments through its expertise in genome editing. The company's pipeline includes several in vivo (administered within the body) programs. NTLA-2001 is currently undergoing a Phase 1 clinical trial for transthyretin amyloidosis, while NTLA-2002 targets hereditary angioedema. Additionally, Intellia is developing various other liver-focused therapies for conditions such as hemophilia A and B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo (processed outside the body) pipeline features NTLA-5001, a candidate for acute myeloid leukemia. The company is also progressing proprietary programs focused on creating engineered cell therapies to address diverse oncological and autoimmune disorders. At the core of Intellia's technology is the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has established multiple licensing and collaboration agreements. These include a partnership with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for treating sickle cell disease, and a co-development agreement with Regeneron Pharmaceuticals, Inc. for potential products against hemophilia A and B. The company also collaborates with Ospedale San Raffaele and holds a strategic alliance with SparingVision SAS to develop novel genomic medicines for ocular diseases, leveraging CRISPR/Cas9 technology. The company, initially known as AZRN, Inc., was founded in 2014 and operates from its headquarters in Cambridge, Massachusetts.
No summaries found.
- Share price
- $12.69
- Market cap
- $1.77B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- John Leonard
- Employees
- 377
- IPO date
- 06/05/2016
- Beta
- 1.819
- Last dividend
- $0.00
- Day range
- $12.14 – $12.98
- 52-week range
- $7.95 – $28.25
- 1-day performance
- 3.85%
- 1-year performance
- 59.62%
- Current drawdown (1Y)
- -55.08%
- CIK
- 0001652130
- CUSIP
- 45826J105
- ISIN
- US45826J1051
- Created
- 07/12/2025, 05:31:06
- Last update
- 23/09/2026, 06:57:49
Track Intellia Therapeutics, Inc. with an AI analyst
See which prediction-market events move NTLA, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema
GlobeNewsWire • STOCK • 13/06/2026, 09:30:00
Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026
GlobeNewsWire • STOCK • 01/06/2026, 09:30:00
Intellia Therapeutics - Steady Progress, Historic Commercial Approval In Sight
Seeking Alpha • STOCK • 31/05/2026, 10:45:00
Intellia Therapeutics, Inc. (NTLA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Seeking Alpha • STOCK • 12/05/2026, 23:40:48
NTLA Q1 Earnings Beat Estimates, Revenues Miss Mark, Pipeline in Focus
Zacks Investment Research • STOCK • 12/05/2026, 14:47:11
Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Misses Revenue Estimates
Zacks Investment Research • STOCK • 11/05/2026, 11:41:06
Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates
GlobeNewsWire • STOCK • 11/05/2026, 09:30:00
Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Zacks Investment Research • STOCK • 07/05/2026, 13:01:03
Intellia Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewsWire • STOCK • 05/05/2026, 09:30:00
Intellia Therapeutics Announces Pricing of Public Offering of Common Stock
GlobeNewsWire • STOCK • 29/04/2026, 09:00:00
NTLA Falls 4% Despite Strong Phase III HAE Data, Initiates Rolling BLA
Zacks Investment Research • STOCK • 28/04/2026, 16:06:11
Intellia (NTLA) Stock: Citigroup Reiterates 'Outperform' on BLA
Market Data • Market Data • 28/04/2026, 13:00:34